Biotech công khai
[search 0]
Thêm

Download the App!

show episodes
 
Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering. Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050. Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.
 
B
BioTech IQ

1
BioTech IQ

Ammon Rivera

Unsubscribe
Unsubscribe
Hàng tháng+
 
Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development, safety/PV and more! We address how each function plays an important role in the drug approval process. We also discuss the people that make up these departments. Get ready to hear about cutting edge development and the people who make it happen!
 
Biotech—it's complicated. A successful product launch requires grit, determination, and clear direction. But let’s be real, the path to launch isn’t a straight one. There are curves, hard turns, and dead ends. Here’s the good news, you don’t have to navigate the complexities alone. Welcome to The Emerging Biotech Leader, where we help biotech leaders maximize the value of their therapeutics from clinical development to product launch.
 
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is p ...
 
Welcome to the RE-LAUNCH of BIOTECH NATION !!! Since 2004, the public radio program "Tech Nation" has followed biotech's journey from the science lab to actual products in its regular segment, "BioTech Nation". With understandable interviews - requiring no background science - BTN attracts a wide audience. From everyday people looking for hope in potential future treatments, to entrepreneurs interested in the experience of their fellow travelers, to venture capitalists seeing possibilities i ...
 
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.
 
San Diego has grown into one of the largest biotechnology hubs in the United States with some very talented people doing very exciting things. Come along with me as I explore the world of biotech, meet some interesting people, and maybe even learn a thing or two. Oh wait… did I mention there will be beer?
 
I
Inside Biotech

1
Inside Biotech

Dr. Yewande Pearse, Kathy Grotsch, Ananta Wadhwa

Unsubscribe
Unsubscribe
Hàng tháng
 
Inside Biotech is an exciting new podcast from BCLA, which focuses on the science behind SoCals most innovative new biotech companies. This monthly podcast, hosted by Dr. Yewande Pearse, Media & Marketing Associate at BCLA, is the perfect way for LA’s biotech community to stay informed about current progress and developments, and features conversations with scientists, entrepreneurs, and investors about the cutting edge science that goes on inside their companies. On Inside Biotech, science ...
 
Horizon 3 is a biotech fund which has been formed to help investors to have a real impact on a range of global health challenges through new bio technologies, aiming to de-risk the investment risks inherent in such a technical area.These podcasts are a series aimed at educating investors on the issues, risks and opportunities involved in investing ion the biotech sector.
 
Encode Ideas authors research on publicly traded micro / small cap healthcare (biotech & medtech) companies. The Plainspoken podcast is an extension of our research, where we will interview executives from micro / small cap health care companies, portfolio managers who invest in micro / small cap healthcare, and key opinion leaders who can offer insights into therapeutics areas of interest to investors. The podcast is for entertainment purposes only and should not be considered financial adv ...
 
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications. Use cases for the DrugPatentWatch platform include: - Branded pharmaceutical global business intelligence and forecasting - Generic drug and API manufacturer portfolio management - Wholesalers preventing overstock of off-patent drugs - Healthcare payer formulary management and budget management
 
Interviews with the researchers, founders, and investors of the BioTech industry. An insiders look into what is going on in the world of BioTech, from curing aging to psychedelic therapy, we interview the game changers of the industry. The unsung hero's that are moving the industry forward in a significant way. The world is going to be a vastly different place in the next 10-20 years because of what's happening in the BioTech industry right now.Human civilization will move forward farther, f ...
 
Loading …
show series
 
In an industry that takes new business naming conventions to extremes, Abpro is a refreshingly clear exception. Brothers Ian Chan (CEO & Co-Founder) and Eugene Chan, M.D., (Chairman & Co-Founder) are antibody pros. The company's pipeline spans no fewer than 8 antibody candidates aimed at COVID-19, cancers including breast, gastric, and liver, and o…
 
Radamés Cordero is the CEO of Melatech and an associate scientist and junior faculty in the department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health where he studies the biology of fungal melanin. As a spin-off of his research, Melatech is a biotech company dedicated to the production of melanin at indu…
 
Biomarkers themselves have been a part of medical research for decades. However, digital biomarkers have become increasingly important to the modern clinical development process. While the term “digital biomarker” is prevalent in discussions around investment, clinical trials, and measuring patient outcomes, a variety of questions surrounding digit…
 
Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackey is the President & CEO of Aristea Therapeutics.Bởi Moira Gunn
 
Bigger plants are better, right? Not always. Control of plant or tree size can have many advantages, and genetic control of 'dwarf' phenotypes has been important in feeding a billion people. The problem is that the changes induced by dwarfing genes can have a negative effect on other aspects of plant biology, so identifying new genes to control siz…
 
Synopsis: Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. Bill entered biotech a little over four years ago following a long life sciences career in pharma, working for companies such as …
 
Avraham Hermon is a Senior Partner at JMB Davis Ben-David, a US Patent Agent and an Israel Patent Attorney. He has a BA in Chemistry and a Master’s in Law.Prior to joining the firm Avraham worked in a number of Israeli pharmaceutical companies including Teva Pharmaceutical Industries where he led a team of patent attorneys in providing opinion on p…
 
2:40 Labiotech.eu news 4:58 SOTIO Biotech 13:43 Eversana 19:37 Carl Borrebaeck 36:42 Concarlo Therapeutics This week, we have four interviews: Franjo Hanzl, vice president commercial development Europe at Eversana; Stacy Blain, founder and CEO of Concarlo Therapeutics; Jens Hennecke, chief business officer at SOTIO Biotech; and Carl Borrebaeck, cha…
 
This week on the podcast Agustin provides updates on key readouts from Affimed and Leap Therapeutics in particular setting the record straight for their recent data readouts. In addition he shares some exciting news regarding a new initiative! If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros…
 
Alzheimer’s, Parkinson’s and ALS, among others, are often grouped as Neurodegenerative Disorders. While they each present a different profile of symptoms, what do they have in common? Dr. Maria Maccecchini, the Founder, President & CEO of Annovis Bio, says, "Sticky proteins".Bởi Moira Gunn
 
2023 is just around the corner, and it's shaping up to be a big year for Umoja Biopharma. The company is on the leading edge of the effort to break the solid tumor barrier with in vivo CAR T-cell therapies, with one such effort currently enrolling patients for a phase 1 trial. It's planning two more INDs in the coming year. This episode of the Busi…
 
Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has the potential to treat other breast cancers as well as ovarian cancer. Dr. Amit Kumar is the President & CEO. More information is available at anixa.com.…
 
The modern era of genetic engineering has opened tremendous opportunities in medicine and agriculture. But who governs when the technology should be applied? Similar questions were asked in the 1970s at the dawn of recombinant DNA technology. In his new book As Gods - A Moral History of the Genetic Age, Prof. Matthew Cobb discusses these watershed …
 
Synopsis: Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, a company that develops medicines to treat patients with rare neurological conditions, including epilepsies and seizure-related disorders. Dr. Levin earned a PhD from Oxford and medical and surgical degrees from Cambridge before moving to the States in the late 1980s and eventuall…
 
Loading …

Hướng dẫn sử dụng nhanh

Google login Twitter login Classic login